<DOC>
	<DOCNO>NCT00249301</DOCNO>
	<brief_summary>The purpose study determine ( 1 ) The side effect toxicities MLN8054 ; ( 2 ) The high dose side effect toxicity severe ; ( 3 ) How MLN8054 absorb general blood circulation eliminate body ; ( 4 ) The level MLN8054 blood need inhibit Aurora A kinase .</brief_summary>
	<brief_title>A Study MLN8054 Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Colonic Neoplasms</mesh_term>
	<criteria>Histologically cytologically confirm metastatic and/or advance solid tumor ( include lymphoma ) standard treatment offer long offer curative lifeprolonging potential Aged 18 year Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Expected survival longer 3 month enrollment study Radiographically clinically evaluable tumor ; however , measurable disease require participation study Suitable venous access conduct blood sample MLN8054 PK Recovered reversible effect prior antineoplastic therapy least 4 week elapse since last exposure cytotoxic chemotherapy radiotherapy least 6 week elapse since exposure nitrosoureas mitomycin C. Patients treat fully human monoclonal antibody must receive treatment antibody least 6 week , treat chimeric monoclonal antibody must receive treatment antibody least 4 week . Patients treat noncytotoxic small molecule drug ( eg , tyrosine kinase inhibitor , Tarceva , hormonal agent , Femara ) must receive treatment drug least 2 week first dose MLN8054 give . Male patient must use appropriate method barrier contraception ( eg , condom ) inform sexual partner must also use reliable method contraception ( eg , birth control pill ) study 21 day last dose study treatment . Female patient must postmenopausal , surgically sterilize , willing use reliable method birth control ( eg , hormonal contraceptive , intrauterine device , diaphragm spermicide , abstinence ) study 21 day last dose study treatment . Able give inform consent conduct studyrelated procedure part normal medical care comply protocol Pregnant lactate Major surgery within 28 day precede first dose study treatment Serious infection within 28 day first dose study treatment Lifethreatening illness unrelated cancer Ongoing nausea vomit severity &gt; Grade 1 diarrhea Known GI disease could interfere oral absorption tolerance MLN8054 Difficulty swallow capsule Inability fast overnight morning dose MLN8054 remain nothing mouth ( [ NPO ] except water prescribe medication ) 2 hour dose MLN8054 Received 4 previous cytotoxic chemotherapeutic regimen , include regimen use adjuvant neoadjuvant therapy . There limit number noncytotoxic therapy ( eg , hormonal immunologic ) patient may receive . Tyrosine kinase inhibitor ( eg , Tarceva Iressa ) consider noncytotoxic compound . Prior treatment highdose chemotherapy , define chemotherapy require use peripheral blood bone marrow stem cell support hematopoietic reconstitution Prior treatment radiation therapy involve &gt; 25 % hematopoietically active bone marrow ( see Table 151 distribution active bone marrow adult ) Clinical and/or radiographic evidence cerebral metastasis . However , patient history central nervous system ( CNS ) metastasis radiographic clinical evidence residual tumor ( eg , follow complete surgical resection ) exclude participation study . Clinically significant abnormality arrhythmias 12lead electrocardiogram ( ECG ) opinion investigator Known suspect human immunodeficiency virus ( HIV ) positive hepatitis B surface antigenpositive status , know suspect active hepatitis C infection Known suspect disorder bilirubin metabolism excretion , include , limited , Gilbert 's syndrome , CriglerNajjar syndrome , DubinJohnson syndrome , Rotor syndrome Inclusion trial investigational drug previous 4 week Admission alcohol abuse inability restrict consumption alcohol 1 standard unit alcohol per day study 21 day last dose study treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2008</verification_date>
	<keyword>Breast Cancer</keyword>
	<keyword>Colon Cancer</keyword>
	<keyword>Pancreatic Cancer</keyword>
	<keyword>Bladder Cancer</keyword>
</DOC>